Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 26 (September 10), 2007: pp. 4127-4136
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.8554

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stupp, R.
Right arrow Articles by Chakravarti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stupp, R.
Right arrow Articles by Chakravarti, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions

Roger Stupp, Monika E. Hegi, Mark R. Gilbert, Arnab Chakravarti

From the Multidisciplinary Oncology Center; Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne; National Center of Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Laboratory of Molecular and Cellular Radiation Neuro-Oncology, Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, MA

Address reprint requests to: Roger Stupp, MD, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland CH-1011; e-mail: roger.stupp{at}chuv.ch

Glioma has been considered resistant to chemotherapy and radiation. Recently, concomitant and adjuvant chemoradiotherapy with temozolomide has become the standard treatment for newly diagnosed glioblastoma. Conversely (neo-)adjuvant PCV (procarbazine, lomustine, vincristine) failed to improve survival in the more chemoresponsive tumor entities of anaplastic oligoastrocytoma and oligodendroglioma. Preclinical investigations suggest synergism or additivity of radiotherapy and temozolomide in glioma cell lines. Although the relative contribution of the concomitant and the adjuvant chemotherapy, respectively, cannot be assessed, the early introduction of chemotherapy and the simultaneous administration with radiotherapy appear to be key for the improvement of outcome. Epigenetic inactivation of the DNA repair enzyme methylguanine methyltransferase (MGMT) seems to be the strongest predictive marker for outcome in patients treated with alkylating agent chemotherapy. Patients whose tumors do not have MGMT promoter methylation are less likely to benefit from the addition of temozolomide chemotherapy and require alternative treatment strategies. The predictive value of MGMT gene promoter methylation is being validated in ongoing trials aiming at overcoming this resistance by a dose-dense continuous temozolomide administration or in combination with MGMT inhibitors. Understanding of molecular mechanisms allows for rational targeting of specific pathways of repair, signaling, and angiogenesis. The addition of tyrosine kinase inhibitors vatalanib (PTK787) and vandetinib (ZD6474), the integrin inhibitor cilengitide, the monoclonal antibodies bevacizumab and cetuximab, the mammalian target of rapamycin inhibitors temsirolimus and everolimus, and the protein kinase C inhibitor enzastaurin, among other agents, are in clinical investigation, building on the established chemoradiotherapy regimen for newly diagnosed glioblastoma.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
M. D. Szeto, G. Chakraborty, J. Hadley, R. Rockne, M. Muzi, E. C. Alvord Jr., K. A. Krohn, A. M. Spence, and K. R. Swanson
Quantitative Metrics of Net Proliferation and Invasion Link Biological Aggressiveness Assessed by MRI with Hypoxia Assessed by FMISO-PET in Newly Diagnosed Glioblastomas
Cancer Res., May 15, 2009; 69(10): 4502 - 4509.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. Stupp, F. Roila, and On behalf of the ESMO Guidelines Working Group
Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv126 - iv128.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Hingtgen, X. Ren, E. Terwilliger, M. Classon, R. Weissleder, and K. Shah
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
Mol. Cancer Ther., November 1, 2008; 7(11): 3575 - 3585.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
N. G. Gottardo and A. Gajjar
Chemotherapy for Malignant Brain Tumors of Childhood
J Child Neurol, October 1, 2008; 23(10): 1149 - 1159.
[Abstract] [PDF]


Home page
The OncologistHome page
A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
Oncologist, September 1, 2008; 13(9): 978 - 992.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
C. Beadle, M. C. Assanah, P. Monzo, R. Vallee, S. S. Rosenfeld, and P. Canoll
The Role of Myosin II in Glioma Invasion of the Brain
Mol. Biol. Cell, August 1, 2008; 19(8): 3357 - 3368.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. Y. Wen and S. Kesari
Malignant Gliomas in Adults
N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507.
[Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
I. Vlassenbroeck, S. Califice, A.-C. Diserens, E. Migliavacca, J. Straub, I. Di Stefano, F. Moreau, M.-F. Hamou, I. Renard, M. Delorenzi, et al.
Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma
J. Mol. Diagn., July 1, 2008; 10(4): 332 - 337.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Murat, E. Migliavacca, T. Gorlia, W. L. Lambiv, T. Shay, M.-F. Hamou, N. de Tribolet, L. Regli, W. Wick, M. C.M. Kouwenhoven, et al.
Stem Cell-Related "Self-Renewal" Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma
J. Clin. Oncol., June 20, 2008; 26(18): 3015 - 3024.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Yang, G. Wu, R. F. Barth, M. R. Swindall, A. K. Bandyopadhyaya, W. Tjarks, K. Tordoff, M. Moeschberger, T. J. Sferra, P. J. Binns, et al.
Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies
Clin. Cancer Res., February 1, 2008; 14(3): 883 - 891.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online